Sep 5, 2025 08:28AM

Oct 24, 2024 03:28AM

Jul 17, 2024 02:28AM

Jul 16, 2024 03:59PM

Feb 8, 2024 02:23AM

Nov 28, 2023 02:29AM

Nov 2, 2023 03:20AM Orexo Q3 2023 Interim Report

Oct 11, 2023 03:01AM

Sep 18, 2023 02:37AM

Jul 18, 2023 02:36AM

Apr 27, 2023 02:33AM

Apr 3, 2023 02:51AM

Feb 3, 2023 02:45AM

Oct 28, 2022 07:00AM Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

Oct 28, 2022 02:21AM

Jul 14, 2022 02:34AM

Apr 28, 2022 02:48AM

Apr 27, 2022 02:22AM

Nov 16, 2021 02:21AM

Oct 18, 2021 11:07AM

Jan 29, 2021 11:06AM Orexo expects FDA filing of OX124 mid 2022

Jan 28, 2021 02:21AM

Jan 27, 2021 02:17AM

Nov 4, 2020 02:13AM

Sep 14, 2020 08:02AM

Sep 9, 2020 11:14AM

Aug 10, 2020 02:09AM

Jul 2, 2020 02:34AM Orexo Launches Deprexis® and Vorvida® in the US and Provides Updated Financial Guidance

Jun 30, 2020 02:28AM

May 11, 2020 02:24AM

Apr 28, 2020 02:46AM

Mar 6, 2020 02:26AM

Jan 30, 2020 03:39AM

Nov 27, 2019 09:46AM

Mar 29, 2019 11:27AM District Court of Delaware Rules that Actavis does not Infringe with their Suboxone® and Subutex® Generics

Jan 7, 2019 02:15AM

Dec 12, 2017 02:49AM

Aug 2, 2017 03:27AM

Mar 1, 2017 02:55AM

Jan 26, 2017 02:18AM

324,230 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All